Cor­rect­ed: West­lake tar­gets $450M for Sei­den­berg's next life sci­ences fund

Life sci­ences VC firm West­lake Vil­lage BioPart­ners is ready to re­stock its cap­i­tal re­serves short­ly af­ter its suc­cess with bring­ing port­fo­lio com­pa­ny Ace­lyrin to one of the biggest IPOs in re­cent biotech mem­o­ry.

The Los An­ge­les ven­ture firm — led by well-known ex-Klein­er Perkins in­vestor Beth Sei­den­berg — eyes a $450 mil­lion fund, per a Thurs­day SEC fil­ing. West­lake’s oth­er found­ing man­ag­ing di­rec­tor, for­mer Am­gen R&D ex­ec­u­tive Sean Harp­er, is not list­ed on the SEC fil­ing as a par­tic­i­pant in the fund.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER